Replies to post #223754 on Biotech Values

[DewDiligence]

If the Botox-biosimilar program is scrapped, it’ll be no big deal (IMO) and RVNC will still get to keep the $25M up-front payment from MYL. The only reason I’m even mentioning this scenario is that investors might misconstrue the (lack of a) read-through to the RT002 program.

[DewDiligence]

RVNC—The only possible near-term event that would matter to me is if there is any change to the timeline of filing the [RT002 BLA].

I’m hoping for a refinement in the guidance from “1H19” to a specific (pre-June) month, “early 2Q19,” or even “mid 2Q19.”